CC
RPRX icon

Corton Capital’s Royalty Pharma RPRX Stock Holding History

Corton Capital’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,859
Closed -$247K – 373
2025
Q2 		$247K Buy
+6,859
New +$227K 0.29% 135
2025
Q1 		– Sell
-10,893
Closed -$278K – 377
2024
Q4 		$278K Buy
+10,893
New +$289K 0.16% 130

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Corton Capital's RPRX Position: Q3 2025 in Review

Corton Capital sold out of Royalty Pharma (RPRX) in Q3 2025, closing a stake of 6,859 shares — an estimated $247K sold.

Corton Capital first reported a position in RPRX in Q4 2024 and held it in 2 quarters. The position peaked at $278K in Q4 2024. 487 funds tracked by Wall St. Rank hold RPRX as of Q3 2025.

  • Corton Capital reported no remaining Royalty Pharma position as of Q3 2025 after selling out during the quarter.
  • Corton Capital sold 6,859 Royalty Pharma shares in Q3 2025, an estimated $247K.
  • Corton Capital first reported a position in Royalty Pharma in Q4 2024 and held it in 2 quarters.
  • Corton Capital's Royalty Pharma position peaked at $278K in Q4 2024.
  • 487 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2025.

Based on Corton Capital's 13F filing for Q3 2025, filed 14 Nov 2025.